|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
|
JP2003509478A
(ja)
*
|
1999-09-21 |
2003-03-11 |
エモリー・ユニバーシティ |
血小板関連障害を処置する方法および組成物
|
|
AR035216A1
(es)
|
2000-12-01 |
2004-05-05 |
Astrazeneca Ab |
Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
|
|
US6287599B1
(en)
*
|
2000-12-20 |
2001-09-11 |
Shire Laboratories, Inc. |
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
|
AR034517A1
(es)
|
2001-06-21 |
2004-02-25 |
Astrazeneca Ab |
Formulacion farmaceutica
|
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
|
WO2003039530A1
(en)
*
|
2001-11-07 |
2003-05-15 |
Synthon B.V. |
Tamsulosin tablets
|
|
JP4882200B2
(ja)
*
|
2001-11-13 |
2012-02-22 |
アステラス製薬株式会社 |
水溶性薬物徐放化技術
|
|
US6811794B2
(en)
*
|
2001-12-20 |
2004-11-02 |
Shire Laboratories, Inc. |
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
|
KR100540035B1
(ko)
*
|
2002-02-01 |
2005-12-29 |
주식회사 태평양 |
다단계 경구 약물 방출 제어 시스템
|
|
GB0203296D0
(en)
*
|
2002-02-12 |
2002-03-27 |
Glaxo Group Ltd |
Novel composition
|
|
CN1326569C
(zh)
*
|
2002-02-26 |
2007-07-18 |
阿斯特拉曾尼卡有限公司 |
含有水溶性纤维素衍生物的iressa药物制剂
|
|
AU2003230805A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Penwest Pharmaceuticals Co. |
Sustained release metoprolol formulations
|
|
SE0201661D0
(sv)
*
|
2002-05-31 |
2002-05-31 |
Astrazeneca Ab |
New salts
|
|
US20040043073A1
(en)
*
|
2002-06-14 |
2004-03-04 |
Chih-Ming Chen |
Pharmaceutical compositions for drugs having pH-dependent solubility
|
|
US8637512B2
(en)
*
|
2002-07-29 |
2014-01-28 |
Glaxo Group Limited |
Formulations and method of treatment
|
|
BR0315731A
(pt)
*
|
2002-10-30 |
2005-09-06 |
Pharmacia Corp |
Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
|
|
US7018658B2
(en)
*
|
2002-11-14 |
2006-03-28 |
Synthon Bv |
Pharmaceutical pellets comprising tamsulosin
|
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
|
US20070009596A1
(en)
*
|
2003-05-14 |
2007-01-11 |
Bruschi Stefano D L |
Controlled drug release composition resistant to in vivo mechanic stress
|
|
US7781424B2
(en)
*
|
2003-05-27 |
2010-08-24 |
Astrazeneca Ab |
Modified release pharmaceutical formulation
|
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
|
GB0317663D0
(en)
*
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Pharmaceutical composition
|
|
US7198653B2
(en)
|
2003-07-31 |
2007-04-03 |
Delavau Llc |
Calcium carbonate granulation
|
|
US20050106253A1
(en)
*
|
2003-11-13 |
2005-05-19 |
Platteeuw Johannes J. |
Pharmaceutical pellets comprising tamsulosin
|
|
ME01316B
(me)
*
|
2004-08-13 |
2013-12-20 |
Boehringer Ingelheim Int |
Formulacija tablete sa produženim oslobađanjem koji sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
|
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
|
WO2006047493A2
(en)
|
2004-10-21 |
2006-05-04 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
|
CA2592605C
(en)
*
|
2004-12-27 |
2010-12-07 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
|
US20060160852A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
|
US20070129402A1
(en)
*
|
2004-12-27 |
2007-06-07 |
Eisai Research Institute |
Sustained release formulations
|
|
US8128952B2
(en)
*
|
2005-01-12 |
2012-03-06 |
Clemson University Research Foundation |
Ligand-mediated controlled drug delivery
|
|
CN101132780A
(zh)
*
|
2005-02-15 |
2008-02-27 |
爵士制药公司 |
缓慢释放取代的吡嗪化合物的剂型和方法
|
|
US20060204575A1
(en)
*
|
2005-03-11 |
2006-09-14 |
Hengsheng Feng |
Amphetamine formulations
|
|
CA2604617C
(en)
*
|
2005-04-28 |
2014-06-17 |
Eisai R&D Management Co., Ltd. |
Composition containing anti-dementia drug
|
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
|
US8920837B2
(en)
|
2005-07-01 |
2014-12-30 |
Rubicon Research Private Limited |
Sustained release dosage form
|
|
DK1909766T3
(en)
*
|
2005-07-28 |
2016-04-04 |
Shire Llc |
PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM
|
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
|
BRPI0615135A2
(pt)
*
|
2005-08-26 |
2016-09-13 |
Bpsi Holdings Inc |
composições de fármacos contendo matrizes de hipromelose de liberação controlada
|
|
ES2620293T3
(es)
|
2005-09-09 |
2017-06-28 |
Paladin Labs Inc. |
Composición de liberación sostenida de fármacos
|
|
EP1937270A1
(en)
*
|
2005-09-21 |
2008-07-02 |
Brystol-Myers Squibb Company |
Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
|
|
US20070092573A1
(en)
*
|
2005-10-24 |
2007-04-26 |
Laxminarayan Joshi |
Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
|
|
WO2007054976A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Panacea Biotec Ltd. |
Lipid based controlled release pharmaceutical composition
|
|
US20070238942A1
(en)
*
|
2006-04-10 |
2007-10-11 |
Esophamet Corp. |
Apparatus and method for detecting gastroesophageal reflux disease (gerd)
|
|
ES2396051T3
(es)
|
2006-04-26 |
2013-02-18 |
Supernus Pharmaceuticals, Inc. |
Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal
|
|
KR100780479B1
(ko)
|
2006-05-08 |
2007-11-28 |
윈셋파마 주식회사 |
이부딜라스트 함유 경구용 제제 및 이의 제조방법
|
|
WO2007131804A1
(en)
|
2006-05-17 |
2007-11-22 |
Synthon B.V. |
Tablet composition with a prolonged release of tamsulosin
|
|
CN101495096A
(zh)
*
|
2006-05-30 |
2009-07-29 |
伊兰制药国际有限公司 |
纳米微粒泊沙康唑制剂
|
|
US9138414B1
(en)
|
2006-09-15 |
2015-09-22 |
Delavau Llc |
Calcium supplement having enhanced absorption
|
|
TW200827336A
(en)
|
2006-12-06 |
2008-07-01 |
Astrazeneca Ab |
New crystalline forms
|
|
US20100081672A1
(en)
*
|
2006-12-07 |
2010-04-01 |
Schering Corporation |
Ph sensitive matrix formulation
|
|
US20100172991A1
(en)
*
|
2007-06-08 |
2010-07-08 |
Henry Joseph Horacek |
Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
|
|
WO2008154339A2
(en)
|
2007-06-08 |
2008-12-18 |
Addrenex Pharmaceuticals, Inc. |
Extended release formulation and method of treating adrenergic dysregulation
|
|
TW200900033A
(en)
*
|
2007-06-21 |
2009-01-01 |
Wen-Qing Li |
Automatic brewing machine
|
|
US20090022789A1
(en)
*
|
2007-07-18 |
2009-01-22 |
Supernus Pharmaceuticals, Inc. |
Enhanced formulations of lamotrigine
|
|
US20090061000A1
(en)
*
|
2007-08-31 |
2009-03-05 |
Astrazeneca Ab |
Pharmaceutical formulation use 030
|
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
|
GB2460915B
(en)
*
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
|
DE202009018024U1
(de)
|
2008-08-01 |
2010-12-09 |
Krka Tovarna Zdravil, D.D., Novo Mesto |
Quetiapin-Zusammensetzung
|
|
AT10562U3
(de)
*
|
2008-12-05 |
2010-01-15 |
Aop Orphan Pharmaceuticals Ag |
Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
|
|
US20100159001A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Cardinal John R |
Extended-Release Pharmaceutical Formulations
|
|
US8465770B2
(en)
*
|
2008-12-24 |
2013-06-18 |
Synthon Bv |
Low dose controlled release tablet
|
|
EP2564839B1
(en)
|
2009-01-09 |
2016-05-11 |
Forward Pharma A/S |
Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
|
|
JPWO2010110436A1
(ja)
|
2009-03-27 |
2012-10-04 |
杏林製薬株式会社 |
塩基性添加剤を含有するマトリックス型徐放性製剤
|
|
SG10201407965XA
(en)
|
2009-12-02 |
2015-02-27 |
Aptalis Pharma Ltd |
Fexofenadine microcapsules and compositions containing them
|
|
WO2011085466A1
(en)
|
2010-01-18 |
2011-07-21 |
Medizone International Inc. |
Bio-terrorism counteraction using ozone and hydrogen peroxide
|
|
US20110217373A1
(en)
*
|
2010-01-29 |
2011-09-08 |
Kumaravel Vivek |
Extended release pharmaceutical compositions of guanfacine hydrochloride
|
|
JP5714562B2
(ja)
|
2010-02-22 |
2015-05-07 |
第一三共株式会社 |
経口用徐放性固形製剤
|
|
EP2540318B1
(en)
|
2010-02-22 |
2018-10-24 |
Daiichi Sankyo Company, Limited |
Sustained-release solid preparation for oral use
|
|
EP2366378A1
(en)
|
2010-03-01 |
2011-09-21 |
Dexcel Pharma Technologies Ltd. |
Sustained-release donepezil formulations
|
|
SI2549983T1
(sl)
*
|
2010-03-25 |
2015-06-30 |
Aop Orphan Pharmaceuticals Ag |
Nova sestava za zdravljenje esencialne trombocitemije
|
|
AU2011256928A1
(en)
*
|
2010-05-24 |
2012-12-20 |
Lupin Limited |
Extended release formulation of pramipexole
|
|
US9011912B2
(en)
|
2010-10-07 |
2015-04-21 |
Abon Pharmaceuticals, Llc |
Extended-release oral dosage forms for poorly soluble amine drugs
|
|
US9060755B2
(en)
|
2010-10-26 |
2015-06-23 |
Medtronic Ardian Luxembourg S.A.R.L. |
Neuromodulation cryotherapeutic devices and associated systems and methods
|
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
WO2012129551A1
(en)
|
2011-03-23 |
2012-09-27 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods and compositions for treatment of attention deficit disorder
|
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
|
JP6123795B2
(ja)
*
|
2012-03-30 |
2017-05-10 |
アステラス製薬株式会社 |
放出制御医薬組成物
|
|
RU2665372C2
(ru)
|
2012-09-03 |
2018-08-29 |
Дайити Санкио Компани, Лимитед |
Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
JP6362601B2
(ja)
|
2012-09-18 |
2018-07-25 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
|
|
US20160022591A1
(en)
*
|
2013-03-15 |
2016-01-28 |
Mylan Inc. |
Extended release pharmaceutical solid dosage formulations
|
|
US9211284B2
(en)
|
2013-04-11 |
2015-12-15 |
Richard Louis Price |
Diagnosis and treatment of P.R.I.C.E. syndrome
|
|
US20140309270A1
(en)
|
2013-04-11 |
2014-10-16 |
Richard Louis Price |
Diagnosis and treatment of a form of autistic spectrum disorder
|
|
US10098848B2
(en)
|
2013-04-11 |
2018-10-16 |
Richard Louis Price |
Inositol-containing comestible units and methods of treatment using the same
|
|
US9603812B2
(en)
|
2013-04-11 |
2017-03-28 |
Richard Louis Price |
Treatment of autistic spectrum disorder
|
|
US20170348417A1
(en)
|
2013-04-11 |
2017-12-07 |
Richard Louis Price |
Treatment of attention deficit disorders and associated symptoms
|
|
EP2796133A1
(en)
|
2013-04-26 |
2014-10-29 |
Salmon Pharma GmbH |
Sustained release guanfacine HCl formulation
|
|
AU2014357518A1
(en)
|
2013-12-03 |
2016-06-09 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
CN103784413A
(zh)
*
|
2014-02-27 |
2014-05-14 |
中国药科大学 |
阿替洛尔pH非依赖型缓释片及其制备方法
|
|
DK2915526T3
(da)
|
2014-03-07 |
2021-09-06 |
Galenicum Health S L U |
Farmaceutiske sammensætninger, der omfatter anagrelid
|
|
CA2947528C
(en)
|
2014-05-01 |
2023-09-05 |
Sun Pharmaceutical Industries Limited |
Extended release suspension compositions
|
|
US10258583B2
(en)
|
2014-05-01 |
2019-04-16 |
Sun Pharmaceutical Industries Limited |
Extended release liquid compositions of guanfacine
|
|
US9962336B2
(en)
|
2014-05-01 |
2018-05-08 |
Sun Pharmaceutical Industries Limited |
Extended release suspension compositions
|
|
US20180104197A9
(en)
|
2014-05-01 |
2018-04-19 |
Sun Pharmaceutical Industries Limited |
Extended release liquid compositions of metformin
|
|
BR112017001968A2
(pt)
|
2014-07-30 |
2017-11-21 |
Sun Pharmaceutical Ind Ltd |
embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
|
|
PL3265085T3
(pl)
|
2015-03-06 |
2022-11-07 |
Auspex Pharmaceuticals, Inc. |
Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
|
|
PL4049660T3
(pl)
|
2016-02-29 |
2025-06-09 |
F. Hoffmann-La Roche Ag |
Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona
|
|
WO2017182852A1
(en)
*
|
2016-04-20 |
2017-10-26 |
Sun Pharmaceutical Industries Limited |
Extended release liquid compositions of guanfacine
|
|
US10369078B2
(en)
|
2016-05-02 |
2019-08-06 |
Sun Pharmaceutical Industries Limited |
Dual-chamber pack for pharmaceutical compositions
|
|
US10238803B2
(en)
|
2016-05-02 |
2019-03-26 |
Sun Pharmaceutical Industries Limited |
Drug delivery device for pharmaceutical compositions
|
|
JP7459458B2
(ja)
*
|
2018-06-28 |
2024-04-02 |
ライオン株式会社 |
内服組成物及びその製造方法
|
|
KR102078462B1
(ko)
*
|
2018-07-24 |
2020-02-17 |
주식회사 디네이쳐 |
질환경 개선 조성물 및 이를 포함하는 개선제
|
|
US12472158B2
(en)
|
2019-02-27 |
2025-11-18 |
Vanderbilt University |
Methods of treating trigeminal nerve pain
|
|
MA56011A
(fr)
*
|
2019-04-05 |
2022-04-06 |
Gedea Biotech Ab |
Formulation de comprimé vaginal
|
|
CN115989022A
(zh)
*
|
2020-07-02 |
2023-04-18 |
阿瑟姆治疗株式会社 |
口服用药物组合物及其制备方法
|
|
EP4292587A1
(en)
|
2022-06-15 |
2023-12-20 |
Sawai Pharmaceutical Co., Ltd. |
Guanfacine hydrochloride containing pharmaceutical preparation
|
|
WO2024189275A1
(en)
|
2023-03-15 |
2024-09-19 |
Sartar Therapeutics Oy |
A pharmaceutical composition for subcutaneous injection of anagrelide
|
|
JP7844541B2
(ja)
*
|
2023-08-29 |
2026-04-13 |
スタンダード ケム アンド ファーム カンパニー リミテッド |
グアンファシンを含む医薬組成物及びその製造方法
|